A

Apontis Pharma AG
XETRA:APPH

Watchlist Manager
Apontis Pharma AG
XETRA:APPH
Watchlist
Price: 9.64 EUR -1.43% Market Closed
Market Cap: 80.3m EUR
Have any thoughts about
Apontis Pharma AG?
Write Note

Apontis Pharma AG
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Apontis Pharma AG
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
A
Apontis Pharma AG
XETRA:APPH
Total Equity
€30.3m
CAGR 3-Years
106%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ATAI Life Sciences NV
NASDAQ:ATAI
Total Equity
$243m
CAGR 3-Years
39%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bayer AG
XETRA:BAYN
Total Equity
€30.6B
CAGR 3-Years
-1%
CAGR 5-Years
-8%
CAGR 10-Years
4%
Merck KGaA
XETRA:MRK
Total Equity
€28.3B
CAGR 3-Years
11%
CAGR 5-Years
9%
CAGR 10-Years
9%
Dermapharm Holding SE
XETRA:DMP
Total Equity
€583.7m
CAGR 3-Years
11%
CAGR 5-Years
18%
CAGR 10-Years
N/A
PharmaSGP Holding SE
XETRA:PSG
Total Equity
€39.8m
CAGR 3-Years
51%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
No Stocks Found

Apontis Pharma AG
Glance View

Market Cap
80.3m EUR
Industry
Pharmaceuticals

APONTIS PHARMA AG engages in the development, promotion, and sale of single pills and other pharmaceutical products. The company is headquartered in Monheim Am Rhein, Nordrhein-Westfalen and currently employs 176 full-time employees. The company went IPO on 2021-05-11. The firm focuses on the commercialization of pharmaceutical products to General Practitioners and engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany.

APPH Intrinsic Value
15.03 EUR
Undervaluation 36%
Intrinsic Value
Price
A

See Also

What is Apontis Pharma AG's Total Equity?
Total Equity
30.3m EUR

Based on the financial report for Dec 31, 2023, Apontis Pharma AG's Total Equity amounts to 30.3m EUR.

What is Apontis Pharma AG's Total Equity growth rate?
Total Equity CAGR 3Y
106%

Over the last year, the Total Equity growth was -27%. The average annual Total Equity growth rates for Apontis Pharma AG have been 106% over the past three years .

Back to Top